Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | KIF11 | P52732 | 5/20 | 0.48 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374123 | 1.00 | IDO1 (0.58) | IDO1ALPIPKMPTGS1XIAP | |
| SCHEMBL30131214 | 1.00 | IDO1 (0.58) | IDO1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL29398539 | 0.98 | IDO1 (0.61) | IDO1ALPIPKMPTGS1XIAP | |
| SCHEMBL7543851 | 0.87 | KIF11 (0.48) | IDO1SLC1A1SLC1A3KIF11KMT2A | |
| SCHEMBL7543855 | 0.87 | KIF11 (0.48) | IDO1SLC1A1SLC1A3KIF11KMT2A | |
| SCHEMBL10996772 | 0.85 | IDO1 (0.56) | IDO1ALPIPKMPTGS1XIAP | |
| SCHEMBL10996770 | 0.85 | IDO1 (0.56) | IDO1ALPIPKMPTGS1XIAP | |
| SCHEMBL19493644 | 0.82 | IDO1 (0.46) | IDO1SLC1A1SLC1A3SLC15A1SLC1A2 | |
| SCHEMBL6576329 | 0.81 | ALPI (0.50) | IDO1ALPIPKMPTGS1XIAP | |
| SCHEMBL6577929 | 0.81 | ALPI (0.50) | IDO1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522636-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | Latvian Institute Of Organic Synthesis (LV) | 2025-03-19 | — | — | EP | claimed |
| US-12162954-B2 | Method for preparing etelcalcetide hydrochloride | KRISAN BIOTECH CO., LTD. (TW) | 2024-12-10 | — | — | US | claimed |
| WO-2023227926-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2023-11-30 | — | — | WO | claimed |
| US-20230043220-A1 | METHOD FOR PREPARING ETELCALCETIDE HYDROCHLORIDE | KRISAN BIOTECH CO., LTD. (TW) | 2023-02-09 | — | — | US | claimed |
| US-20260028378-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | LATVIAN INST ORGANIC SYNTHESIS (LV) | 2026-01-29 | — | — | US | disclosed |
| EP-4522636-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | Latvian Institute Of Organic Synthesis (LV) | 2025-03-19 | — | — | EP | disclosed |
| US-12162954-B2 | Method for preparing etelcalcetide hydrochloride | KRISAN BIOTECH CO., LTD. (TW) | 2024-12-10 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-117866190-A | Non-viral gene delivery vector, preparation and application | 浙江大学长三角智慧绿洲创新中心 | 2024-04-12 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023227926-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2023-11-30 | — | — | WO | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | IDO1 3149/4885ALPI 2410/4885PKM 2766/4885 |
| US-20260028378-A1 | CHEMICALLY MODIFIED ENGINEERED SPIDER SILK PROTEINS | SGTA, PTMS, SCTR | IDO1 1769/4885ALPI 3912/4885PKM 4694/4885 |
| US-12162954-B2 | Method for preparing etelcalcetide hydrochloride | PTH1R, ECE2, PTMS | IDO1 3989/4885ALPI 769/4885PKM 3792/4885 |
| US-20230043220-A1 | METHOD FOR PREPARING ETELCALCETIDE HYDROCHLORIDE | PTH1R, ECE2, PTMS | IDO1 3989/4885ALPI 769/4885PKM 3792/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | IDO1 3149/4885ALPI 2410/4885PKM 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.